fda warning letter bpc-157 compounding Survey: Half of Peptide-Users Aren't Aware of Approval Status fda warning letter bpc-157 unapproved
Description
Gut Inflammation Given that BPC-157 is derived from the human gastric juice protein, there is particular interest in its potential for treating gut-related conditions, such as ulcers and inflammatory bowel disease (IBD, including Crohn's disease and ulcerative colitis)
6.5 months in the Pd arm (HR, 0.596
This may affect the dosing schedule and the frequency of injections
A more serious concern with long term GLP-1RA usage relates to the potential increased risk for PDAC due to promoting cellular proliferation
